Literature DB >> 15878491

Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease.

Luigi Allegra1, Francesco Blasi, PierLuigi Diano, Roberto Cosentini, Paolo Tarsia, Marco Confalonieri, Katerina Dimakou, Vincenzo Valenti.   

Abstract

We analyzed 795 sputa from 315 patients (233 males, mean age 69.3+/-8.8 years, mean number of exacerbations 2.52/patient) with acute exacerbations of moderate-to-severe chronic obstructive pulmonary disease (COPD) (mean steady-state FEV1 42.5+/-7.8% of predicted). 581/795 sputa were considered adequate. Sputum was analyzed by a quali-quantitative colorimetric scale allowing both color distinction and color degree of intensity. Quantitative culture was then performed (threshold: >10(6)CFU/mL). Samples were distinguished in mucoid (145) and purulent (436) sputa. Absence of bacterial growth was observed in 22% and 5% of mucoid and purulent sputa, respectively. Among mucoid sputa, Gram positive bacterial growth occurred more commonly compared to Gram negative and Pseudomonas aeruginosa/Enterobacteriaceae (56%, 24%, 20%, respectively). In purulent sputa, Gram positives were found in 38% of cases, Gram negatives in 38%, and P. aeruginosa/Enterobacteriaceae in 24%. We evaluated whether functional impairment (FEV1) orientates as to the infectious etiology of exacerbations. Significant differences were observed in the distribution of pathogens. Gram negative and P. aeruginosa/Enterobacteriaceae were isolated more frequently in the sputum when FEV1 was <35%. Our study indicates that purulent sputum is strongly associated with bacterial growth in COPD exacerbations. Deepening sputum color (from yellowish to brownish) was associated with increased yield of Gram negative and P. aeruginosa/Enterobacteriaceae.

Entities:  

Mesh:

Year:  2004        PMID: 15878491     DOI: 10.1016/j.rmed.2004.10.020

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  22 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

2.  Development and Validation of a Multivariable Prediction Model to Identify Acute Exacerbation of COPD and Its Severity for COPD Management in China (DETECT Study): A Multicenter, Observational, Cross-Sectional Study.

Authors:  Yan Yin; Jinfu Xu; Shaoxi Cai; Yahong Chen; Yan Chen; Manxiang Li; Zhiqiang Zhang; Jian Kang
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-09-05

Review 3.  Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2007-12

4.  Inflammatory biomarkers in sputum predict COPD exacerbations.

Authors:  Ellen Tufvesson; Marie Ekberg; Leif Bjermer
Journal:  Lung       Date:  2013-05-21       Impact factor: 2.584

5.  Sputum colour for diagnosis of a bacterial infection in patients with acute cough.

Authors:  Attila Altiner; Stefan Wilm; Walter Däubener; Christiane Bormann; Michael Pentzek; Heinz-Harald Abholz; Martin Scherer
Journal:  Scand J Prim Health Care       Date:  2009       Impact factor: 2.581

6.  Increased leptin/leptin receptor pathway affects systemic and airway inflammation in COPD former smokers.

Authors:  Andreina Bruno; Marinella Alessi; Simona Soresi; Anna Bonanno; Loredana Riccobono; Angela Marina Montalbano; Giusy Daniela Albano; Mark Gjomarkaj; Mirella Profita
Journal:  J Inflamm Res       Date:  2011-05-20

7.  Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.

Authors:  Robert Wilson; Antonio Anzueto; Marc Miravitlles; Pierre Arvis; Jeff Alder; Daniel Haverstock; Mila Trajanovic; Sanjay Sethi
Journal:  Eur Respir J       Date:  2011-12-01       Impact factor: 16.671

Review 8.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 9.  Lung microbiology and exacerbations in COPD.

Authors:  Victoria Beasley; Priya V Joshi; Aran Singanayagam; Philip L Molyneaux; Sebastian L Johnston; Patrick Mallia
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-08-31

Review 10.  Clinical applications of azithromycin microspheres in respiratory tract infections.

Authors:  Francesco Blasi; Stefano Aliberti; Paolo Tarsia
Journal:  Int J Nanomedicine       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.